YLL545
YLL545 is a type of vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. YLL545 can inhibit VEGF-induced phosphorylation of VEGFR2 and the activation of downstream signaling factors (like phosphorylated STAT3 and phosphorylated ERK1/2) in human umbilical vein endothelial cells (HUVEC) . YLL545 can suppress the proliferation, migration, invasion, and angiogenesis of HUVEC. YLL545 can induce apoptosis in breast cancer mice and inhibit tumor growth[1].
Product Specifications
CAS Number
[1423126-69-5]
UNSPSC
12352005
Target
Apoptosis; ERK; STAT; VEGFR
Type
Reference compound
Related Pathways
Apoptosis; JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/yll545.html
Smiles
O=C(NC1=CC=CC(C(F)(F)F)=C1)NC2=CC=C(OC3=C4C(NN=C4)=NC=N3)C=C2
Molecular Formula
C19H13F3N6O2
Molecular Weight
414.34
References & Citations
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-164551/YLL545-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-164551/
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human HTR3A shRNA (UAS) - Lentiviral human HTR3A shRNA (UAS, RFP) (25)
